Oral MDS Treatment ASTX727 Equivalent to IV Dacogen in PIII Study: Otsuka

Otsuka Pharmaceutical said on June 7 that the oral anticancer agent ASTX727, which is being developed by its US subsidiary Astex Pharmaceuticals, demonstrated equivalence to the intravenously administered DNA methylation inhibitor Dacogen (decitabine) in a PIII trial for myelodysplastic syndrome...read more